Proteolytic Cleavage and Loss of Function of Biologic Agents That Neutralize Tumor Necrosis Factor in the Mucosa of Patients With Inflammatory Bowel Disease

• Published in: Gastroenterology (New York, N.Y. 1943) Vol. 149; no. 6; pp. 1564 - 1574.e3
• Main Authors: Biancheri, Paolo, Brezski, Randall J, Di Sabatino, Antonio, Greenplate, Allison R, Soring, Keri L, Corazza, Gino R, Kok, Klaartje B, Rovedatti, Laura, Vossenkämper, Anna, Ahmad, Nadja, Snoek, Susanne A, Vermeire, Severine, Rutgeerts, Paul, Jordan, Robert E, MacDonald, Thomas T
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.11.2015
• Subjects: Adalimumab - metabolism; Antibodies, Monoclonal, Humanized - metabolism; Biological Factors - metabolism; Biological Factors - pharmacology; Biopsy; Case-Control Studies; Colitis, Ulcerative - drug therapy; Colitis, Ulcerative - immunology; Colitis, Ulcerative - metabolism; Colon - immunology; Colon - metabolism; Colon - pathology; Crohn Disease - drug therapy; Crohn Disease - immunology; Crohn Disease - metabolism; Epitopes - metabolism; Etanercept - metabolism; Female; Gastroenterology and Hepatology; Humans; Immunoblotting - methods; Immunoglobulin G - metabolism; Inflammation; Inflammatory Bowel Diseases - drug therapy; Inflammatory Bowel Diseases - immunology; Inflammatory Bowel Diseases - metabolism; Infliximab - metabolism; Intestinal Mucosa - drug effects; Intestinal Mucosa - immunology; Intestinal Mucosa - metabolism; Male; Matrix Metalloproteinase 12 - metabolism; Matrix Metalloproteinase 3 - metabolism; Middle Aged; Proteolysis - drug effects; Therapy; Tumor Necrosis Factor-alpha - metabolism; PBS; Therapy; CD; Inflammation; IBD; phosphate-buffered saline; TNF; UC; inflammatory bowel disease; MMP; tumor necrosis factor; enzyme-linked immunosorbent assay; matrix metalloproteinase; HC; healthy control; ELISA

Background & Aims Many patients with inflammatory bowel disease (IBD) fail to respond to anti–tumor necrosis factor (TNF) agents such as infliximab and adalimumab, and etanercept is not effective for treatment of Crohn’s disease. Activated matrix metalloproteinase 3 (MMP3) and MMP12, which are i...